SC 13G: Cullinan Therapeutics, Inc.
Ticker: CGEM · Form: SC 13G · Filed: Apr 24, 2024 · CIK: 1789972
| Field | Detail |
|---|---|
| Company | Cullinan Therapeutics, Inc. (CGEM) |
| Form Type | SC 13G |
| Filed Date | Apr 24, 2024 |
| Risk Level | low |
| Pages | 7 |
| Reading Time | 8 min |
| Sentiment | neutral |
Sentiment: neutral
Topics: sc-13g
AI Summary
SC 13G filing by Cullinan Therapeutics, Inc..
Risk Assessment
Risk Level: low
FAQ
What type of filing is this?
This is a SC 13G filing submitted by Cullinan Therapeutics, Inc. (ticker: CGEM) to the SEC on Apr 24, 2024.
What is the risk level of this SC 13G filing?
This filing has been assessed as low risk.
How long is this filing?
Cullinan Therapeutics, Inc.'s SC 13G filing is 7 pages with approximately 2,024 words. Estimated reading time is 8 minutes.
Where can I view the full SC 13G filing?
The complete filing is available on SEC EDGAR. You can also read the AI-decoded analysis with risk assessment and key highlights on ReadTheFiling.
Filing Stats: 2,024 words · 8 min read · ~7 pages · Grade level 6.8 · Accepted 2024-04-24 17:50:03
Filing Documents
- e663545_sc13g-ct.htm (SC 13G) — 99KB
- 0001193805-24-000557.txt ( ) — 101KB
(a)
Item 1(a). Name of Issuer: Cullinan Therapeutics, Inc.
(b)
Item 1(b). Address of Issuer's Principal Executive Offices: One Main Street, Suite 1350 Cambridge, Massachusetts, 02142
(a)
Item 2(a). Name of Person Filing: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P.
(b)
Item 2(b). Address of Principal Business Office, or if None, Residence: James E. Flynn, Deerfield Mgmt, L.P., Deerfield Partners, L.P. and Deerfield Management Company, L.P., 345 Park Avenue South, 12th Floor, New York, NY 10010
(c)
Item 2(c). Citizenship: Deerfield Mgmt, L.P., Deerfield Management Company, L.P. and Deerfield Partners, L.P. - Delaware limited partnerships; James E. Flynn – United States citizen
(d)
Item 2(d). Title of Class of Securities: Common Stock
(e)
Item 2(e). CUSIP Number: 230031106 Item 3. If This Statement is Filed Pursuant to Rule 13d-1(b), or 13d-2(b) or (c), Check Whether the Person Filing is a: (a) Broker or dealer registered under Section 15 of the Exchange Act. (b) Bank as defined in Section 3(a)(6) of the Exchange Act. (c) Insurance company as defined in Section 3(a)(19) of the Exchange Act. (d) Investment company registered under Section 8 of the Investment Company Act. (e) An investment adviser in accordance with Rule 13d-1(b)(1)(ii)(E); (f) An employee benefit plan or endowment fund in accordance with Rule 13d-1(b)(1)(ii)(F); (g) A parent holding company or control person in accordance with Rule 13d-1(b)(1)(ii)(G); (h) A savings association as defined in Section 3(b) of the Federal Deposit Insurance Act; (i) A church plan that is excluded from the definition of an investment company under Section 3(c)(14) of the Investment Company Act; CUSIP No. 230031106 13G Page 7 of 9 (j) A non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J); (k) Group, in accordance with Rule 13d-1(b)(1)(ii)(K). If filing as a non-U.S. institution in accordance with Rule 13d-1(b)(1)(ii)(J), please specify the type of institution: ___________________________________________ Item 4. Provide the following information regarding the aggregate number and percentage of the class of securities of the issuer identified in Item 1. (a) Amount beneficially owned**: Deerfield Mgmt, L.P. - 3,283,824 shares Deerfield Management Company, L.P. - 3,283,824 shares Deerfield Partners, L.P. - 3,283,824 shares James E. Flynn – 3,283,824 shares (b) Percent of class**: Deerfield Mgmt, L.P. – 5.71% Deerfield Management Company, L.P. – 5.71% Deerfield Partners, L.P. – 5.71% James E. Flynn – 5.71% (c) Number of shares as to which such person has**: (i) Sole power to vote or to direct the vote: All Reporting Persons - 0 (ii)